The perplexing question of trained immunity vs adaptive memory in COVID-19.
BCG vaccination
SARS-CoV-2
adaptive immune enhancement
air pollution
alive vaccines
mucosal immunity
severity variation
trained immunity
type III hypersensitivity
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
06
05
2020
revised:
26
05
2020
accepted:
27
05
2020
pubmed:
30
5
2020
medline:
17
12
2020
entrez:
30
5
2020
Statut:
ppublish
Résumé
The wide spectrum of symptoms observed in coronavirus disease 2019 appears to defy explanation. Apart from geographic limitation to people with prior exposure to other coronaviruses and air pollutants, inflammatory comorbidities and older ages are also among the main factors of susceptibility to severe illness. The unusual epidemiological data pointed out in children and African territories have revealed new insights in host-pathogen interplay with more focus on epigenetic regulation of cognitive compartments belonging to innate immunity. Should trained immunity be proven to be involved in timely immune responsiveness against severe acute respiratory syndrome coronavirus 2 and that adaptive memory could be detrimental, both treatment regimens and vaccine design will tremendously change accordingly with more focus on upper respiratory tissue innate immunity to subdue this threat underway.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1858-1863Subventions
Organisme : General Directorate of Research and Technology Development
ID : Ministry of Higher Education and Scientific Resear
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Zirui Tay M, Meng Poh C, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363-374. https://doi.org/10.1038/s41577-020-0311-8
Kerboua K. NLR: a cost-effective nomogram to guide therapeutic interventions in COVID-19 [published online ahead of print June 1, 2020]. Immunol Invest. 2020:1-9. https://doi.org/10.1080/08820139.2020.1773850
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation, and treatment coronavirus (COVID-19). Treasure Island, FL: StatPearls Publishing; 2020. https://www.ncbi.nlm.nih.gov/books/NBK554776/
Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-afocused review for clinicians. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.04.023
Peeples L. News feature: avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci USA. 2020;117(15):8218-8221.
Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;20(6):689-696. https://doi.org/10.1016/S1473-3099(20)30198-5
Cristiani L, Mancino E, Matera L, et al. Will children reveal their secret? The coronavirus dilemma. Eur Respir J. 2020;55(4). https://doi.org/10.1183/13993003.00749-2020
Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020. https://doi.org/10.1016/j.trsl.2020.04.007
Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J, et al. Trained immunity: a tool for reducing susceptibility and severity of SARS-CoV2 infection. CellPress. 2020;181:969-977. https://doi.org/10.1016/j.cell.2020.04.042
Coronavirus disease 2019 (COVID-19-situation report 71. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200331-sitrep-71-covid-19.pdf?sfvrsn=4360e92b_6. Accessed June 3, 2020.
Lakshmi Priyadarsini S, Suresh M. Factors influencing the epidemiological characteristics of pandemic COVID 19: a TISM approach. Int J Healthcare Manag. 2020;13(2):89-98. https://doi.org/10.1080/20479700.2020.1755804
https://www.statista.com/statistics/1093256/novel-coronavirus-2019ncov-deaths-worldwide-by-country/. Accessed June 3, 2020.
Otu A, Ebenso B, Labonte R, Yaya S. Tackling COVID-19: can the African continent play the long game? J Glob Health. 2020;10(1):010339.
WHO. WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. https://www.who.int/dg/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed April 23, 2020.
Kobia F, Gitaka J. COVID-19: are Africa's diagnostic challenges blunting response effectiveness? AAS Open Research. 2020;3:4. https://doi.org/10.12688/aasopenres.13061.1
Daw MA, El-Bouzedi AH. Modelling the epidemic spread of COVID-19 virus infection in Northern African countries. Travel Med Infect Dis. 2020. https://doi.org/10.1016/j.tmaid.2020.101671
Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrobial Agents. 2020;55:105946.
Mehtar S, Preiser W, Lakhe NA, et al. Limiting the spread of COVID-19 in Africa: one size mitigation strategies do not fit all countries. Lancet Glob Health. 2020. https://doi.org/10.1016/S2214-109X(20)30212-6
Woodward A High temperatures and muggy weather might make the new coronavirus less contagious, a group of experts says. Business insider India. 2020. https://www.businessinsider.in/science/news/high-temperaturesand-muggy-weather-might-make-the-newcoronavirus-less-contagious-a-group-of-experts-says/articleshow/74697538.cms. Accessed March 30, 2020.
Quaresima V, Naldini MM, Cirillo DM. The prospects for the SARS-CoV-2 pandemic in Africa. EMBO Mol Med. 2020. https://doi.org/10.15252/emmm.202012488
Safadi MA. The intriguing features of COVID-19 in children and its impact on the pandemic. J Pediatr. 2020. https://doi.org/10.1016/j.jped.2020.04.001
Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome [published online ahead of print May 6, 2020]. J Microbiol Immunol Infect. 2020;53(3):425-435. https://doi.org/10.1016/j.jmii.2020.04.015
Du W, Yu J, Wang H, et al. Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China. Infection. 2020;48(3):445-452. https://doi.org/10.1007/s15010-020-01427-2
Achoki T, Alam U, Were L, et al. COVID-19 pandemic in the African continent: forecasts of cumulative cases, new infections, and mortality. MedRxiv. 2020. https://doi.org/10.1101/2020.04.09.20059154
https://www.tuttitalia.it/lombardia/statistiche/cittadini-stranieri-2019/. Accessed June 3, 2020.
Conticini E, Frediani B, Caro D. Can atmospheric pollution be considered a co-factor in extremely high level of SARS-CoV-2 lethality in Northern Italy? Environ Pollut. 2020;261:114465. https://doi.org/10.1016/j.envpol.2020.114465
Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55:2000547. https://doi.org/10.1183/13993003.00547-2020
Cao Q, Chen Y-C. SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics. J Formos Med Assoc. 2020;119:670-673. https://doi.org/10.1016/j.jfma.2020.02
Li H, Chen K, Liu M, Xu H, Xu Q. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.04.001
Chen Z, Fu J, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020:1-7. https://doi.org/10.1007/s12519-020-00345-5
Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;20:689-696. https://doi.org/10.1016/S1473-3099(20)30198-5
Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92:548-551. https://doi.org/10.1002/jmv.25722
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720. https://doi.org/10.1056/NEJMoa2002032
Roth A, Garly ML, Jensen H, Nielsen J, Aaby P. Bacillus Calmette-Guérin vaccination and infant mortality. Expert Rev Vaccines. 2006;5(2):277-293.
Soliman R, Brassey J, Plüddemann A, Heneghan C Does BCG vaccination protect against acute respiratory infections and COVID-19? A rapid review of current evidence. 2020. On behalf of the Oxford COVID-19 Evidence Service Team, Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: Role of inflammation triggers and cytokines. Front Immunol. 2018;9:586.
Scarpa R, Costa L, Del Puente A, Caso F. Role of thymopoiesis and inflamm-aging in COVID-19 phenotype. Pediatr Neonatol. 2020;61:364-365. https://doi.org/10.1016/j.pedneo.2020.04.001
Lau CM, Adams NM, Geary CD, et al. Epigenetic control of innate and adaptive immune memory. Nat Immunol. 2018;19:963-972.
Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA. 2012;109:17537-17542.
Christine SB, Mihai GN. A small jab-a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 2013;34:431-439. https://doi.org/10.1016/j.it.2013.04.004
Kumaki Y, Salazar AM, Wandersee MK, Barnard DL. Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model. Antiviral Res. 2017;139:1-12.
Arts RJW, Moorlag SJCFM, Novakovic B, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. 2018;23:89-100.
Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. 2018;379:138-149.
Wardhana Datau EA, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43:185-190.
Ohrui T, Nakayama K, Fukushima T, Chiba H, Sasaki H. Prevention of elderly pneumonia by pneumococcal, influenza and BCG vaccinations. Japanese J Geriatr. 2005;42:34-36.
Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85:12201-12215.
Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA. 2005;102:797-801.
Ho MS, Chen WJ, Chen HY, et al. Neutralizing antibody response and SARS severity. Emerg Infect Dis. 2005;11:1730-1737.
Yip MS, Leung NH, Cheung CY, et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virol J. 2014;11:82.
Jaume M, Yip MS, Cheung CY, et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J Virol. 2011;85:10582-10597.
Acosta PL, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol. 2015;23:189-195.
Halstead SB. Immune enhancement of viral infection. Prog Allergy. 1982;31:301-364.
Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microb Infect. 2020;22:72-73.